Co-Authors
This is a "connection" page, showing publications co-authored by LEE M ELLIS and EDMUND SCOTT KOPETZ.
Connection Strength
0.515
-
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117.
Score: 0.121
-
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9.
Score: 0.092
-
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 2009 May 01; 69(9):3842-9.
Score: 0.088
-
Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clin Colorectal Cancer. 2021 03; 20(1):e53-e60.
Score: 0.049
-
Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015 Feb 15; 21(4):899-906.
Score: 0.033
-
Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.
Score: 0.032
-
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013 Dec 15; 119(24):4231-41.
Score: 0.030
-
GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis. 2012 Jul; 33(7):1327-31.
Score: 0.027
-
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51.
Score: 0.021
-
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008 Nov 10; 26(32):5254-60.
Score: 0.021